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The Effect of an Oral Care Intervention in Decreasing the
Expression of Proinflammatory Cytokines in Patients Receiving
Chemoradiation for Oral Cancer: A Randomized Clinical Trial
N.J. Sanfilippo,1 R. Vasconcelos,2 J. Moya,3 D. Malamud,2 C. Barber,2
B.E. Smith,1 M. DeLacure,4 R. Kerr,2 B. Schmidt,2 D. Myssiorek,4
and P. Corby4; 1NYU Langone Medical Center, New York, NY, 2New York
University College of Dentistry, New York, NY, 3New York University
Langone Medical Center, New York, NY, 4New York University School of
Medicine, New York, NY
Purpose/Objective(s): Oral mucositis (OM) is one of the most debili-
tating adverse effects in patients undergoing radiation therapy (RT),
chemoradiation therapy, or both. Currently, there are no effective ther-
apies or preventive treatments for OM; rather, most suggested treatments
are palliative in nature. Physiologically, chemotherapy (CT) and RT
evoke a profound inflammatory response, resulting in damage to the
vascular endothelium. The release of proinflammatory mediators is
responsible for mucosal injury and compromises the integrity of the
protective epithelial barrier, which can result in an increased suscepti-
bility to infection. The objective of this pilot study was to associate the
effects of a novel oral care protocol on OM severity and to evaluate
salivary proinflammatory cytokines in cancer patients undergoing RT or
CT/RT.
Materials/Methods: A total of 16 subjects undergoing RT or CT/RT were
enrolled prior to starting treatment. All subjects received a baseline stan-
dard of care oral/dental prophylaxis plus fluoride application prior to the
start of RT or CT/RT. Patients were assigned to an oral health interven-
tional group (IG) or control group (CG). Subjects assigned to the CG
followed a biweekly treatment schedule in which they had their teeth
brushed by a dental professional and were asked to follow standard of care
(SOC) oral hygiene instructions at home. Subjects randomized to the IG
received the Oral Mucosal Deterging and Periodontal Debridement
(OMDP) protocol and attended weekly treatment visits at which they had
their teeth brushed by a dental professional, periodontal debridement, tooth
polishing, and flossing. Subsequently, the cleansing and deterging of the
oral mucosal surfaces was performed using a soft-bristled toothbrush and
an antibacterial agent (alcohol-free chlorhexidine mouth rinse). Subjects in
the IG were instructed to continue to follow the OMDP protocol at home.
Stimulated whole saliva samples were collected at baseline (prior to OM
development), on the onset of OM, during cancer treatment, and 2 months
after the end of RT or CT/RT. Changes in the levels of proinflammatory
cytokines were measured.
Results: Salivary inflammatory biomarkers, noted in levels of IL-10, IL-
13, IL-4, and TNF-a had a significant increase in the CG and reduced or
stayed the same under IG.
Conclusion: These results suggest that overall inflammation was consis-
tently higher as compared to baseline with control treatment and lower
than or similar to baseline with the OMDP treatment, providing encour-
agement for the effectiveness of the oral care protocol as a coadjuvant
treatment for this population.
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Three-Dimensionally Printed Bolus in Head and Neck Electron
Radiation therapy
D.A. Elliott,1 J. Walker,2 and J.M. Holland1; 1Oregon Health and Science
University, Portland, OR, 2Oregon Health & Science University, Portland,
OR
Purpose/Objective(s): When treating head and neck cutaneous or other
superficial cancers with electron radiation therapy, custom bolus is often
used to optimize dose distribution to improve treatment volume coverageand minimize dose to normal tissues. We aim to improve on this custom
bolus technique with patient-specific 3-dimensionally printed bolus.
Materials/Methods: Following computed tomographic simulation, the
patient DICOM imaging data is transferred to the radiation treatment
planning system. Target volumes and organs at risk are contoured and a
plan is created using a standard, noncustom bolus technique. Following
completion of the standard plan, a custom bolus is then created as a
DICOM-RT structure with forward planning in an attempt to decrease
unnecessary dose to organs at risk and increase treatment volume coverage
and dose homogeneity. Custom bolus is tagged with a marker to assist in
orientation and alignment during patient setup. An in-house algorithm is
then used to translate the custom bolus from DICOM-RT to stereo-
lithography file format to transfer to a 3-dimensional printer.
Results: Our institution has successfully modeled custom bolus and con-
verted the bolus to appropriate format for 3-dimensional printing; creating
personalized bolus for individual patients that can be used in electron ra-
diation therapy to the head and neck. Our preclinical model supports
improved treatment volume coverage and decreased dose to normal tissues
with the printed custom bolus. Images of the comparative dosimetric
evaluation of the printed custom bolus to standard bolus electron radiation
therapy will be presented.
Conclusion: We have developed a model to attempt to personalize head
and neck electron radiation therapy with a 3-dimensionally printed custom
bolus. This model is currently under preclinical testing for head and neck
cancer.
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Induction Chemotherapy Followed by Concurrent Chemoradiation
Therapy Versus Concurrent Chemoradiation Therapy Upfront in
Locally Advanced Oral Cavity Cancer: Systematic Review and Meta-
Analysis of Individual Data
G.N. Marta, Sr,1 R. Riera,2 R.I. Haddad,3 E. Cohen,4 G. Rabinowits,5
and L.P. Kowalski6; 1Department of Radiation Oncology Hospital Sı́rio-
Libanês and Instituto do Câncer do Estado de São Paulo - Faculdade de
Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 2Brazilian
Cochrane Center and Discipline of Emergency Medicine and
EvidenceeBased Medicine / Universidade Federal de São Paulo e Escola
Paulista de Medicina (UNIFESPeEPM), São Paulo, Brazil, 3Department
of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
School and Department of Medicine, Brigham and Women’s Hospital,
Boston, MA, 4University of California San Diego, La Jolla, CA, 5Head and
Neck Oncology Program /Harvard Medical School, Dana Farber Cancer
Institute, Boston, MA, 6Department of Head and Neck Surgery and
Otorhinolaryngology AC. Camargo Cancer Center, Sao Paulo, Brazil
Purpose/Objective(s): The initial treatment for locally advanced oral
cavity squamous cell carcinoma (SCC) comprises surgery followed by
radiation therapy with or without chemotherapy. However, nonsurgical
treatment could be an option. This study was performed to evaluate the
effectiveness of induction chemotherapy in nonsurgical protocols for oral
cavity SCC patients.
Materials/Methods: Randomized controlled trials evaluating sequential
therapy (induction chemotherapy followed by chemoradiation therapy
[Chemo group]) versus chemoradiation therapy alone (Control group) in
head and neck cancer were analyzed. Two of the authors independently
evaluated the studies regarding eligibility criteria and risk of bias.
Results: Three studies fulfilled the eligibility criteria. All of them included
different sites of locally advanced head and neck SCC. The individual data
of oral cavity cancer patients were retrieved from 2 studies (Paradigm and
Decide trials). Data from the third study were not retrieved, and this trial
was not considered for analysis. A total of 65 patients were randomly
assigned to the Chemo group (nZ34) and the Control group (nZ31). Both
trials were classified as having low risk of bias. No significant overall
benefit in favor of induction chemotherapy was found regarding mortality
rate (Chemo group, 9/34; Control group, 8/31 [3-year mortality:
Volume 94  Number 4  2016 Posters 883heterogeneity: X2Z0.00, dfZ1 (PZ.97); I2Z0%; test for overall effect:
ZZ0.04, PZ.97) and progression-free survival (Chemo group 9/34;
Control group 12/31 [3-year progression-free rate: heterogeneity:
X2Z0.07, dfZ1 (PZ.79); I2Z0%; test for overall effect: ZZ1.05,
PZ.29]).
Conclusion: Induction chemotherapy when administered before chemo-
radiation therapy did not improve clinical outcomes in comparison to
upfront chemoradiation therapy in patients with locally advanced oral
cavity cancer.
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Risk Factors for Local, Regional, or Distant Recurrence in Human
PapillomavirusePositive Oropharyngeal Cancer
J.J. Caudell, T. Strom, A.O. Naghavi, J.M. Frakes, L.B. Harrison,
and A. Trotti; H. Lee Moffitt Cancer Center and Research Institute, Tampa,
FL
Purpose/Objective(s): Human papillomavirus (HPV)-associated squa-
mous cell carcinomas of the oropharynx are increasingly seen as a separate
disease entity from smoking-associated oropharyngeal cancers, with a
much higher likelihood of cure. The current American Joint Commission
on Cancer (AJCC) staging system for HPV-positive oropharyngeal cancer
is not prognostic for outcome. We evaluated a variety of potential prog-
nostic factors in order to propose potential new components for a staging
system.
Materials/Methods: After gaining institutional review board approval, we
queried an institutional database for patients with HPV or p16-positive
nonmetastatic oropharyngeal cancers treated with definitive radiation
therapy (RT), and 245 cases were identified. Patient, tumor, and treatment
factors were abstracted from the charts. In addition, pretreatment imaging
was reviewed, including computed tomography (CT) in 99.6%, positron
emission tomography/CT in 94.3%, and magnetic resonance imaging in
7.3% to obtain precise size, location, number, and extent of primary and
nodes. Outcomes, including local control (LC), regional control (RC),
locoregional control (LRC), and freedom from distant metastases (FFDM)
were calculated from the end of RT and estimated via Kaplan-Meier
method. Comparisons were made via log-rank test.
Results: Median follow-up of patients alive at last contact was 36 months.
All patients were treated with definitive RT alone (nZ38, 15.4%) or
concurrent systemic therapy and RT (nZ209, 84.6%). LC was seen in 239
of 245 patients, for a 3-year LC rate of 97.8%. There were no statistically
significant prognostic factors for local control, including tumor size or
invasion of adjacent structures. RC was achieved in 235 of 245 patients
(95.3% at 3 years). RC was less likely if there were 5 or more nodes (1-4
vs 5, PZ.05), or if a lymph node was present in level 4 (level 3 or above
vs level 4, PZ.005). Distant metastases occurred in 21 patients, for a 3-
year FFDM rate of 91.4%. Lower rates of FFDM were associated with a
lymph node greater than 6 cm (PZ.02), bilateral lymphadenopathy (uni-
lateral vs bilateral, PZ.034), 5 or more nodes (1-4 vs 5, P<.001), or if a
lymph node was present in level 4 (level 3 or above vs level 4, P<.001).
Conclusion: Outcomes for patients with HPV-associated oropharyngeal
cancer treated with definitive RT are excellent. The increasing burden of
adenopathy, either by size, number, or bilateral involvement, or location in
level 4 portended a higher risk of regional failure or metastasis. These
factors may provide a basis for altering staging.
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Low-Level Laser Therapy and Laser Debridement for Management
of Oral Mucositis in Patients With Head and Neck Cancer Receiving
Chemotherapy and Radiation
E. Allan,1 C. Barney,1 S. Baum,2 T. Kessling,3 V.M. Diavolitsis,1
D. Blakaj,1 J.C. Grecula,1 J.W. Rocco,4 M. Van Putten,3 and A.D. Bhatt1;
1The James Cancer Hospital and Solove Research Institute, WexnerMedical Center at The Ohio State University, Department of Radiation
Oncology, Columbus, OH, 2The Ohio State University Wexner Medical
Center, College of Medicine, Columbus, OH, 3The James Cancer Hospital
and Solove Research Institute, Wexner Medical Center at The Ohio State
University, Department of Maxillofacial Prosthodontics, Columbus, OH,
4The James Cancer Hospital and Solove Research Institute, Wexner
Medical Center at The Ohio State University, Department of
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Purpose/Objective(s): Oral mucositis (OM) is a very common side effect
of head and neck radiation therapy (RT) and concurrent chemotherapy and
radiation (CRT) leading to severe pain, infection, weight loss, higher rates
of hospitalization, higher financial cost of treatment, and breaks in therapy
resulting in increased morbidity and reduced treatment efficacy. The 2014
guidelines from The Mucositis Study Group of the Multinational Associ-
ation of Supportive Care in Cancer included a suggestion that low-level
laser therapy (LLLT) was useful for the prevention of high-grade OM in
patients receiving head and neck RT alone, but no comment could be made
regarding its efficacy in the therapeutic setting for severe OM during RT or
CRT. Our objective is to describe the technical aspects of the laser regimen
we use in this setting and relate the qualitative experience we have had thus
far.
Materials/Methods: Since 2013, 53 patients were referred to dentistry for
laser therapy for significant and bothersome Radiation Therapy Oncology
Group grade 2-3 OM, either during or after RT/CRT. Our regimen uses 2
lasers; a class IV Er, Cr: YSGG laser (l Z2.780 mm), as well as a class IV
diode laser (l Z940 nm). The first laser is used to debride the entire
surface of the ulcerated areas. Settings are 0.25 to 0.75 watts, 15 to 20 pps,
0 water, and 90 air flow rate. The next laser is then used as biostimulation
for pain relief during CRT and for wound healing after CRT is completed.
Instrument settings are 0.6 watts, 12 joules, continuous wave pulse (CW)
for 20 seconds per site and 0.2 watts, (CW), 4 joules, 20 seconds per site
for each situation, respectively. Treatments were administered once or
twice weekly depending on severity and continued until complete reso-
lution of ulcerations.
Results: Forty-one patients started laser treatments either during or
within 1 month of RT/CRT completion. Twelve patients initiated treat-
ments over 1 month after RT/CRT completion. All patients experienced
full clinical resolution of oral ulcerations. The number of treatments
patients received ranged from 2 to 15 with a median number of 7.
Qualitatively, patients tended to report significant early pain relief,
especially during the first 48 hours following laser treatments. Providers
also felt that patients tended to heal more quickly once treatment was
initiated, though, without a comparison group at this point, no definitive
conclusion can be reached.
Conclusion: This report highlights the technical aspects of LLLT and our
regimen for managing severe mucositis. Our qualitative experience thus far
suggests benefits in pain relief and quicker recovery from severe mucositis.
Additional studies are underway evaluating the feasibility, efficacy, and
quality of life metrics.
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A Comparative Study of Patient-Reported Quality of Life,
Xerostomia, and Dysgeusia in Oropharyngeal Squamous Cell
Carcinoma (OPSCC) Treated With Volumetric Modulated Arc Therapy
(VMAT) or Proton Pencil Beam Scanning (PBS)
P. Ahn,1 A. Lin,2 O. Zhou,1 J.N. Lukens,1 and S. Sharma3; 1University of
Pennsylvania, Philadelphia, PA, 2Department of Radiation Oncology,
University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania,
Philadelphia, PA, United States
Purpose/Objective(s): Treatment for OPSCC can affect a number of
outcomes related to quality of life (QOL). We explore differences in
measures such as xerostomia, dysgeusia, weight loss, pain, and overall
